Republic of Moldova vs Syrian Arab Republic: Average cost of multi drug-resistant tuberculosis treatment
Republic of Moldova
824 constant 2022 US$
in 2024
Syrian Arab Republic
785 constant 2022 US$
in 2024
Republic of Moldova rank
60th
Syrian Arab Republic rank
63rd
Average cost of multi drug-resistant tuberculosis treatment over time
- Republic of Moldova
- Syrian Arab Republic
How they compare
Republic of Moldova currently reports 824 constant 2022 US$ against 785 constant 2022 US$ in Syrian Arab Republic, a difference of 39 constant 2022 US$.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Syrian Arab Republic ahead.
Republic of Moldova ranks 60th and Syrian Arab Republic ranks 63rd of 92 countries.
Syrian Arab Republic has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Republic of Moldova | Syrian Arab Republic | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,572 constant 2022 US$ | 3,000 constant 2022 US$ | 428 constant 2022 US$ | Syrian Arab Republic |
| 2020s | 1,372 constant 2022 US$ | 4,182 constant 2022 US$ | 2,810 constant 2022 US$ | Syrian Arab Republic |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Republic of Moldova or Syrian Arab Republic?
- Republic of Moldova, at 824 constant 2022 US$ against 785 constant 2022 US$ in Syrian Arab Republic as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Republic of Moldova and Syrian Arab Republic?
- 39 constant 2022 US$, with Republic of Moldova ahead.
- How many years of comparable data are there for Republic of Moldova and Syrian Arab Republic?
- 8 years are reported by both, from 2017 to 2024.
- How do Republic of Moldova and Syrian Arab Republic rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Republic of Moldova ranks 60th and Syrian Arab Republic ranks 63rd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.